학술논문
CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
Document Type
Article
Author
Hickman, Richard A.; Gedvilaite, Erika; Ptashkin, Ryan; Reiner, Anne S.; Cimera, Robert; Nandakumar, Subhiksha; Price, Adam; Vanderbilt, Chad; Fahy, Tara; Young, Robert J.; Miller, Alexandra M.; Mellinghoff, Ingo K.; Rosenblum, Marc K.; Ladanyi, Marc; Arcila, Maria E.; Zhang, Yanming; Brannon, A. Rose; Bale, Tejus A.
Source
Subject
*SURVIVAL rate
*ASTROCYTOMAS
*HETEROZYGOSITY
*
*
Language
ISSN
0001-6322
Abstract
We verified intermediate OS of I CDKN2A/B i HEMIDEL between I CDKN2A/B i HOMDEL/mutant and neutral tumors (Fig. 1c), approximating the OS of tumors with I CDKN2A/B i copy loss (median survival: 3.0 years, CI: 1.4 years-NR) even after excluding hypermutant tumors [[10]]. [Extracted from the article]